Why fentanyl kills

Fentanyl is a mu-opioid receptor agonist approximately 100 times more potent than morphine as an analgesic, with rapid onset and short duration, and it crosses the blood-brain barrier quickly. NIDA states that as little as 2 mg can be fatal. Death is respiratory. Opioid-induced respiratory depression is compounded, in some exposures, by skeletal muscle rigidity that stiffens the chest wall — what one review calls a "double whammy of a depressed respiratory drive and a mechanical restriction to breathing." Because the fentanyls are highly lipid-soluble, overdose deaths have been described occurring within five minutes, against more than thirty for heroin.^{[1, 2, 3, 4]}

The reversal myth: renarcotization

Naloxone displaces fentanyl from the receptor, but it does not stay there. Naloxone's half-life in adults runs roughly 30 to 80 minutes; fentanyl's elimination half-life is 3 to 7 hours. When the antagonist clears before the agonist, respiratory depression can return — renarcotization. Clinical reference guidance instructs that patients who respond to naloxone be monitored 6 to 12 hours precisely because some opioids have a much longer half-life than the antidote, and notes that repeated doses are commonly required. Fentanyl respiratory depression is documented as harder to reverse than heroin's, often needing multiple or higher doses. A successful reversal is where the standard-of-care inquiry begins, not where it ends.^{[2, 3, 4, 5]}

The adulteration era: what naloxone cannot reverse

Xylazine is a veterinary alpha-2 adrenergic agonist, not an opioid. NIDA is explicit that naloxone and nalmefene do not reverse xylazine's effects. CDC surveillance found the monthly share of illicitly-manufactured-fentanyl deaths with xylazine detected rose 276 percent, from 2.9 percent in January 2019 to 10.9 percent in June 2022. Medetomidine, a substantially more potent alpha-2 agonist, followed: it was detected in 72 percent of illegal opioid samples tested in Philadelphia in late 2024, and 165 patients across three health systems were hospitalized with a severe withdrawal syndrome, 91 percent of them requiring intensive care. Neither compound appears on standard five-panel urine screens.^{[7, 8, 9]}

Past fentanyl: the nitazenes

The supply keeps moving. Nitazenes — benzimidazole opioids with no accepted U.S. medical use — are now present in the American drug supply. Published comparisons place etonitazene at roughly 1,000 times the potency of morphine and 10 to 20 times that of fentanyl, with protonitazene about twice fentanyl's potency and metonitazene approximately equipotent. Because their chemistry differs from conventional opioids, immunoassays routinely used for opioid screening are largely ineffective for most nitazenes, and commonly used fentanyl test strips fail to detect them. Reversal has required high or repeated naloxone doses and, in some cases, continuous infusion. A drug nobody tested for is not a drug that was absent.^[10]

The number is not the cause

Postmortem redistribution alters drug concentrations after death. Lipophilic, highly protein-bound drugs with a large volume of distribution are most affected, and cardiac blood is unreliable next to peripheral blood — sampling site alone can produce an erroneous interpretation. For fentanyl specifically, postmortem concentrations have measured up to nine times higher than in vivo serum at the same dose, with no clear correlation between dose and concentration. A two-year county laboratory review found living impaired drivers with blood fentanyl from 0.5 to 303 ng/mL, against postmortem central blood of 0.6 to 636 ng/mL — ranges that overlap almost entirely. Tolerance widens the overlap further.^{[6, 11, 12, 13]}

But-for causation in federal death-results prosecutions

Under 21 U.S.C. § 841(b)(1), a defendant faces not less than twenty years when "death or serious bodily injury results from the use of such substance." In Burrage v. United States, 571 U.S. 204 (2014), Justice Scalia wrote for the Court that "at least where use of the drug distributed by the defendant is not an independently sufficient cause" of death or serious bodily injury, the enhancement does not apply "unless such use is a but-for cause of the death or injury." A contributing-factor instruction is error. The syllabus confirms, citing Alleyne, that the element goes to the jury beyond a reasonable doubt.^{[14, 15, 16, 17]}

Drug-induced homicide is a different animal

Thirty-one states and the District of Columbia had drug-induced homicide laws as of May 1, 2024 — a 33 percent increase over the 24 states in 2018 — according to the Center for Public Health Law Research at Temple University Beasley School of Law, which tracks these statutes across all fifty states, D.C., and federal law. They are not uniform. Some are standalone offenses, some operate through felony-murder theories, and four states — Arizona, Colorado, Florida, and Oklahoma — authorize a death sentence. Mens rea, causation standards, and available defenses differ jurisdiction to jurisdiction, and none of them is automatically bound by the federal but-for rule.^{[19, 20]}

What Rule 702 now demands of the expert

Since the December 1, 2023 amendment, Federal Rule of Evidence 702 requires the proponent to demonstrate to the court that it is "more likely than not" that each reliability condition is satisfied, and expressly requires that "the expert's opinion reflects a reliable application of the principles and methods to the facts of the case." In synthetic-opioid litigation that lands squarely on overstatement. An expert who converts one postmortem concentration into a cause-of-death conclusion, or a population-level lethal-dose figure into an individualized opinion about a tolerant decedent, is asserting more than the underlying method can carry.^[18]

What the science actually says